Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3300054 · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| LY3300054 | EXPERIMENTAL | LY3300054 given intravenously (IV) on day 1 and day 15 of a 28 day cycle or LY3300054 given IV on day 1 of a 21 (or 28) day cycle. |
| LY3300054 + Ramucirumab | EXPERIMENTAL | LY3300054 and ramucirumab given IV on day 1 and day 15 of a 28 day cycle or ramucirumab given IV on day 1 and day 8 and LY3300054 given IV on day 1 of a 21 day cycle. |
| Abemaciclib + LY3300054 | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + Abemaciclib (Concurrent Dosing) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + Abemaciclib | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. This arm will only be initiated if required. |
| LY3300054 + Merestinib | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle. |
| LY3300054 Expansion (Metastatic Cutaneous Melanoma) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 Expansion (MSI-H Solid Tumors) | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 of a 28 day cycle. |
| : LY3300054 + Abemaciclib (HR+, HER2- Breast Cancer) Expansion | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and abemaciclib given orally every 12 hours of a 28 day cycle. |
| LY3300054 + LY3321367 Expansion (PD-1/PD-L1 Naïve, MSI-H) | EXPERIMENTAL | LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 + LY3321367 Expansion | EXPERIMENTAL | LY3300054 and LY3321367 given IV on day 1 and day 15 of a 28 day cycle. |
| LY3300054 + Merestinib (Pancreatic Cancer) Expansion | EXPERIMENTAL | LY3300054 given IV on day 1 and day 15 and merestinib given orally once daily of a 28 day cycle. |
| Name | Type | Description |
|---|---|---|
| LY3300054 | DRUG | Administered IV |
| Ramucirumab | DRUG | Administered IV |
| Abemaciclib | DRUG | Administered orally |
| Merestinib | DRUG | Administered orally |
| LY3321367 | DRUG | Administered IV |
Inclusion Criteria: * Histologic or cytologic confirmation of advanced solid tumor. * For LY3300054 + abemaciclib only: No participants with liver metastases. Participants must have normal aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin. * For LY3...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
LY3300054 is an investigational small molecule being studied for the treatment of advanced refractory solid tumors, including microsatellite instability-high (MSI-H) solid tumors, cutaneous melanoma, pancreatic cancer, and breast cancer (HR+HER2-). It is currently in Phase 1 clinical development and is not yet approved.
LY3300054 is an anti-PD-L1 checkpoint antibody. It targets the PD-L1 protein, which is involved in immune checkpoint pathways. By binding to PD-L1, it is designed to modulate the immune response against tumor cells. This mechanism is being evaluated in the context of advanced solid tumors.
LY3300054 is developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical research to evaluate this investigational therapy in patients with advanced refractory solid tumors.
LY3300054 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug is no longer in active clinical trials according to the available data.
LY3300054 has been studied in one clinical trial, identified as NCT02791334. This Phase 1 study evaluated the drug alone and in combination in participants with advanced refractory solid tumors. The trial has been completed and enrolled 164 participants across multiple countries.
Yes, LY3300054 is an anti-PD-L1 checkpoint antibody. It is designed to target PD-L1, a protein that can help tumors evade the immune system. This investigational drug is being developed for use in oncology, specifically for advanced solid tumors, and is currently in Phase 1 trials.